An engineered CX3CR1 antagonist endowed with anti-inflammatory activity
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Identification of a chemokine analogue that antagonized CX3CL1-CX3CR1-dependent responses both in vitro and in vivo Chemokines are mainly involved in the recruitment of leukocytes into tissues, a key feature of inflammation. Through its unique receptor CX3CR1, the chemokine CX3CL1 participates in diverse inflammatory processes including arterial atherosclerosis and cerebral or renal inflammation. Using a phage display strategy, we engineered a hCX3CL1 analog (named F1) with a modified N terminus. F1 bound specifically to cells expressing hCX3CR1 and had a Kd value close to that of native CX3CL1. F1 was not a signaling molecule and did not induce chemotaxis, calcium flux, or CX3CR1 internalization. However, it potently inhibited the CX3CL1-induced calcium flux and chemotaxis in CX3CR1-expressing primary cells of human and murine origin with an IC50 of 5–50 nM. It also efficiently inhibited the cell adhesion mediated by the CX3CL1-CX3CR1 axis. Finally, in a noninfectious murine model of peritonitis, F1 strongly inhibited macrophage accumulation. These data reveal a prototype molecule that is the first bona fide antagonist of hCX3CR1. This molecule could be used as a lead compound for the development of a novel class of anti-inflammatory substances that act by inhibiting CX3CR1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 2×
“thioglycollate was not altered significantly in CX3CR1 mice [62, 66], we found here that the peritoneal macrophage population decreased dramatically after F1 or F1-Ig injections (Fig.”
BackgroundThe many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523 · cited 1×
“Chemokines are a family of small, secreted proteins (typically 8–10 kDa) that are involved in leukocyte trafficking in homeostatic and inflammatory conditions [1].”
BackgroundMonitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G., & Geissmann, F. (2007) · Science · doi:10.1126/science.1142883 · Cited by 1,973
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 2×
“The genetic ablation of mCX3CR1 leads to decreased atherogenesis but to increased brain inflammation and pain facilitation [10– 13], to increased microglial neurotoxicity [14], and to early AMD [15].”
BackgroundImmune cell migration in inflammation: present and future therapeutic targets
Luster, A. D., Alon, R., & von Andrian, U. H. (2005) · Nature Immunology · doi:10.1038/ni1275 · Cited by 1,313
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152 · cited 1×
“Two major monocyte populations have been described in mice, varying according to the expression levels of CX3CR1 and Ly6C [58–60] or 7/4 [61].”
BackgroundSubpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response
Sunderkötter, C., Nikolic, T., Dillon, M. J., van Rooijen, N., Stehling, M., Drevets, D. A., & Leenen, P. J. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4410 · Cited by 1,124
Crump, M. P., Gong, J., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana‐Seisdedos, F., Virelizier, J., Baggiolini, M., Sykes, B. D., & Clark‐Lewis, I. (1997) · The EMBO Journal · doi:10.1093/emboj/16.23.6996 · Cited by 731 · cited 1×
“As is generally the case for chemokines [27, 28], the N terminus of CX3CL1 plays the largest role in interaction with CX3CR1 [29].”
BackgroundCombadière, C., Feumi, C., Raoul, W., Keller, N., Rodéro, M., Pézard, A., Lavalette, S., Houssier, M., Jonet, L., Picard, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31692 · Cited by 618 · cited 4×
“The genetic ablation of mCX3CR1 leads to decreased atherogenesis but to increased brain inflammation and pain facilitation [10– 13], to increased microglial neurotoxicity [14], and to early AMD [15].”
BackgroundInfluentialSelf-citationDecreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Lesnik, P., Haskell, C. A., & Charo, I. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15555 · Cited by 487
Cited by
Emerging targets in neuroinflammation-driven chronic pain
Ji, R.-R., Xu, Z.-Z., & Gao, Y.-J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4334 · Cited by 1,101
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Perineural invasion and associated pain in pancreatic cancer
Bapat, A. A., Hostetter, G., Von Hoff, D. D., & Han, H. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3131 · Cited by 501
Microglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis
Marchesi, F., Piemonti, L., Mantovani, A., & Allavena, P. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.001 · Cited by 260
Metadata
- Authors
- Dorgham, K., Ghadiri, A., Hermand, P., Rodero, M., Poupel, L., Iga, M., Hartley, O., Gorochov, G., Combadière, C., & Deterre, P.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-01
- Volume
- 86
- Issue
- 4
- Pages
- 903-911
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2133311030
- Cited by
- 78
- References
- 14
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. https://app.cochat.ai/papers/10.1189/jlb.0308158
- The paper
- Dorgham, K., Ghadiri, A., Hermand, P., Rodero, M., Poupel, L., Iga, M., Hartley, O., Gorochov, G., Combadière, C., & Deterre, P. (2009). An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. Journal of Leukocyte Biology. https://doi.org/10.1189/jlb.0308158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.